Cart
sales@molnova.com
KKI-5 TFA(97145-43-2 free base)
CAS No. ——
KKI-5 TFA(97145-43-2 free base)( —— )
Catalog No. M30078 CAS No. ——
KKI-5 (TFA) is a specific tissue kallikrein inhibitor.Kki-5 (TFA) can reduce breast cancer cell infiltration.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameKKI-5 TFA(97145-43-2 free base)
-
NoteResearch use only, not for human use.
-
Brief DescriptionKKI-5 (TFA) is a specific tissue kallikrein inhibitor.Kki-5 (TFA) can reduce breast cancer cell infiltration.
-
DescriptionKKI-5 (TFA) is a specific tissue kallikrein inhibitor.Kki-5 (TFA) can reduce breast cancer cell infiltration.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorKallikrein
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight887.9
-
Molecular FormulaC37H56F3N11O11
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:Ac-Pro-Phe-Arg-Ser-Val-Gln-NH2
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Deshpande MS, et al. Mapping the binding site of tissue kallikrein: preparation and testing of all possible substrate analog inhibitors homologous with the sequence of kininogen between Ser386 and Gln392. J Med Chem. 1992 Aug 21;35(17):3094-102.
molnova catalog
related products
-
Tecarfarin
Tecarfarin (ATI-5923) is an orally active, potent vitamin K epoxide reductase (VKOR) antagonist and cannabinoid-1 receptor inverse agonist with antithrombotic activity, which attenuates abdominal pain and increases intestinal transit in mice.
-
SARM1-IN-2
SARM1-IN-2 is a potent SARM1 inhibitor for the study of metabolic and neurological related diseases.
-
α-Terpineol
α-Terpineol has antitumour anti-inflammatory and antimicrobial activities it inhibits the growth of tumour cells through a mechanism that involves inhibition of the NF-kappaB pathway.
